Gilead Sciences (GILD)
Market Price (2/7/2026): $152.21 | Market Cap: $189.2 BilSector: Health Care | Industry: Biotechnology
Gilead Sciences (GILD)
Market Price (2/7/2026): $152.21Market Cap: $189.2 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.4%, Dividend Yield is 2.1% | Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% | Key risksGILD key risks include [1] looming patent expirations and subsequent generic competition for its highly profitable HIV franchise and [2] pipeline setbacks, Show more. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 38% | ||
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 33%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 31%, CFO LTM is 9.7 Bil, FCF LTM is 9.2 Bil | ||
| Low stock price volatilityVol 12M is 29% | ||
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.4%, Dividend Yield is 2.1% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 38% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 33%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 31%, CFO LTM is 9.7 Bil, FCF LTM is 9.2 Bil |
| Low stock price volatilityVol 12M is 29% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. |
| Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% |
| Key risksGILD key risks include [1] looming patent expirations and subsequent generic competition for its highly profitable HIV franchise and [2] pipeline setbacks, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Gilead Sciences (GILD) stock has gained about 30% since 10/31/2025 because of the following key factors:
1. Positive Phase 3 Clinical Trial Results for Trodelvy. The publication of full results from the late-stage ASCENT-04/KEYNOTE-D19 study in The New England Journal of Medicine on January 21, 2026, significantly boosted investor confidence. The study, which evaluated Trodelvy in combination with Keytruda for first-line PD-L1+ metastatic triple-negative breast cancer, met its primary endpoint by demonstrating a 35% reduced risk of disease progression or death, and extended median progression-free survival to 11.2 months compared to 7.8 months for Keytruda plus chemotherapy. These findings position Trodelvy plus Keytruda as a potential new standard of care and support expanded label filings.
2. FDA Approval and Commercial Launch of Yeztugo for HIV Prevention. Gilead's new HIV prevention drug, Yeztugo (lenacapavir), received FDA approval and subsequently launched as a twice-yearly injectable for pre-exposure prophylaxis (PrEP). This expanded offering is expected to broaden Gilead's market potential within its strong HIV franchise and is projected to become a blockbuster asset, with annual sales potentially surpassing $5 billion by 2031.
Show more
1. Positive Phase 3 Clinical Trial Results for Trodelvy. The publication of full results from the late-stage ASCENT-04/KEYNOTE-D19 study in The New England Journal of Medicine on January 21, 2026, significantly boosted investor confidence. The study, which evaluated Trodelvy in combination with Keytruda for first-line PD-L1+ metastatic triple-negative breast cancer, met its primary endpoint by demonstrating a 35% reduced risk of disease progression or death, and extended median progression-free survival to 11.2 months compared to 7.8 months for Keytruda plus chemotherapy. These findings position Trodelvy plus Keytruda as a potential new standard of care and support expanded label filings.
2. FDA Approval and Commercial Launch of Yeztugo for HIV Prevention. Gilead's new HIV prevention drug, Yeztugo (lenacapavir), received FDA approval and subsequently launched as a twice-yearly injectable for pre-exposure prophylaxis (PrEP). This expanded offering is expected to broaden Gilead's market potential within its strong HIV franchise and is projected to become a blockbuster asset, with annual sales potentially surpassing $5 billion by 2031.
Show more
Stock Movement Drivers
Fundamental Drivers
The 28.1% change in GILD stock from 10/31/2025 to 2/6/2026 was primarily driven by a 27.5% change in the company's Net Income Margin (%).| (LTM values as of) | 10312025 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 119.00 | 152.50 | 28.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 28,862 | 29,086 | 0.8% |
| Net Income Margin (%) | 21.9% | 27.9% | 27.5% |
| P/E Multiple | 23.5 | 23.4 | -0.4% |
| Shares Outstanding (Mil) | 1,245 | 1,243 | 0.2% |
| Cumulative Contribution | 28.1% |
Market Drivers
10/31/2025 to 2/6/2026| Return | Correlation | |
|---|---|---|
| GILD | 28.1% | |
| Market (SPY) | 1.3% | 10.7% |
| Sector (XLV) | 9.3% | 44.5% |
Fundamental Drivers
The 37.7% change in GILD stock from 7/31/2025 to 2/6/2026 was primarily driven by a 34.3% change in the company's Net Income Margin (%).| (LTM values as of) | 7312025 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 110.78 | 152.50 | 37.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 28,734 | 29,086 | 1.2% |
| Net Income Margin (%) | 20.8% | 27.9% | 34.3% |
| P/E Multiple | 23.1 | 23.4 | 1.0% |
| Shares Outstanding (Mil) | 1,246 | 1,243 | 0.2% |
| Cumulative Contribution | 37.7% |
Market Drivers
7/31/2025 to 2/6/2026| Return | Correlation | |
|---|---|---|
| GILD | 37.7% | |
| Market (SPY) | 9.6% | 10.7% |
| Sector (XLV) | 21.5% | 38.1% |
Fundamental Drivers
The 61.3% change in GILD stock from 1/31/2025 to 2/6/2026 was primarily driven by a 6162.1% change in the company's Net Income Margin (%).| (LTM values as of) | 1312025 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 94.56 | 152.50 | 61.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 28,298 | 29,086 | 2.8% |
| Net Income Margin (%) | 0.4% | 27.9% | 6162.1% |
| P/E Multiple | 935.8 | 23.4 | -97.5% |
| Shares Outstanding (Mil) | 1,247 | 1,243 | 0.3% |
| Cumulative Contribution | 61.3% |
Market Drivers
1/31/2025 to 2/6/2026| Return | Correlation | |
|---|---|---|
| GILD | 61.3% | |
| Market (SPY) | 15.8% | 24.5% |
| Sector (XLV) | 8.8% | 53.2% |
Fundamental Drivers
The 101.9% change in GILD stock from 1/31/2023 to 2/6/2026 was primarily driven by a 126.9% change in the company's Net Income Margin (%).| (LTM values as of) | 1312023 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 75.53 | 152.50 | 101.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 27,136 | 29,086 | 7.2% |
| Net Income Margin (%) | 12.3% | 27.9% | 126.9% |
| P/E Multiple | 28.4 | 23.4 | -17.8% |
| Shares Outstanding (Mil) | 1,255 | 1,243 | 1.0% |
| Cumulative Contribution | 101.9% |
Market Drivers
1/31/2023 to 2/6/2026| Return | Correlation | |
|---|---|---|
| GILD | 101.9% | |
| Market (SPY) | 76.2% | 21.4% |
| Sector (XLV) | 23.8% | 46.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GILD Return | 30% | 24% | -2% | 19% | 37% | 22% | 211% |
| Peers Return | 23% | 18% | -15% | 4% | 18% | 9% | 65% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| GILD Win Rate | 58% | 33% | 42% | 67% | 67% | 100% | |
| Peers Win Rate | 58% | 62% | 37% | 48% | 60% | 80% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| GILD Max Drawdown | 0% | -20% | -12% | -21% | -3% | -4% | |
| Peers Max Drawdown | -7% | -8% | -23% | -10% | -14% | -1% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ABBV, MRK, BMY, PFE, JNJ. See GILD Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/6/2026 (YTD)
How Low Can It Go
| Event | GILD | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -21.3% | -25.4% |
| % Gain to Breakeven | 27.1% | 34.1% |
| Time to Breakeven | 232 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -32.6% | -33.9% |
| % Gain to Breakeven | 48.3% | 51.3% |
| Time to Breakeven | 691 days | 148 days |
| 2018 Correction | ||
| % Loss | -31.8% | -19.8% |
| % Gain to Breakeven | 46.7% | 24.7% |
| Time to Breakeven | 1,439 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -34.4% | -56.8% |
| % Gain to Breakeven | 52.4% | 131.3% |
| Time to Breakeven | 1,392 days | 1,480 days |
Compare to ABBV, MRK, BMY, PFE, JNJ
In The Past
Gilead Sciences's stock fell -21.3% during the 2022 Inflation Shock from a high on 12/29/2021. A -21.3% loss requires a 27.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
AI Analysis | Feedback
Analogy 1: Amgen for antiviral drugs, with a growing oncology pipeline.
Analogy 2: Like a Pfizer or Merck, but a leader in revolutionary HIV and Hepatitis C treatments, and now expanding into oncology.
AI Analysis | Feedback
- Biktarvy: A complete regimen for the treatment of HIV-1 infection in certain adult and pediatric patients.
- Descovy: Used for the treatment of HIV-1 infection and for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1.
- Epclusa: A pan-genotypic, once-daily treatment for adults with chronic hepatitis C virus (HCV) infection.
- Veklury (remdesivir): An antiviral medication used for the treatment of COVID-19 in hospitalized patients and some non-hospitalized patients.
- Trodelvy: An antibody-drug conjugate used to treat certain types of metastatic breast cancer and metastatic urothelial cancer.
- Yescarta: A CAR T-cell therapy approved for the treatment of certain types of large B-cell lymphoma and follicular lymphoma.
- Vemlidy: A once-daily oral medication for the treatment of chronic hepatitis B virus (HBV) infection in adults.
AI Analysis | Feedback
Gilead Sciences (GILD) Major Customers
Gilead Sciences primarily sells its pharmaceutical products to other companies, specifically a limited number of wholesale drug distributors. These distributors then supply the products to pharmacies, hospitals, and other healthcare providers.
According to its financial filings, three wholesale customers each accounted for more than 10% of Gilead's total product sales for the years ended December 31, 2023, 2022, and 2021:
- AmerisourceBergen Corporation (Symbol: ABC)
- Cardinal Health, Inc. (Symbol: CAH)
- McKesson Corporation (Symbol: MCK)
AI Analysis | Feedback
null
AI Analysis | Feedback
Daniel O'Day, Chairman and Chief Executive Officer
Mr. O'Day joined Gilead Sciences in March 2019. Prior to this, he served as the Chief Executive Officer of Roche Pharmaceuticals for over three decades, holding numerous executive positions across their pharmaceutical and diagnostics divisions in North America, Europe, and Asia. He was a member of Roche's Corporate Executive Committee and served on the boards of public and private companies, including Genentech, Flatiron Health, and Foundation Medicine.
Andrew Dickinson, Chief Financial Officer
Andrew Dickinson serves as the Chief Financial Officer for Gilead Sciences. The provided information does not indicate if he founded or managed other companies, sold companies he was previously involved with, or has a pattern of managing companies backed by private equity firms.
Johanna Mercier, Chief Commercial Officer
Ms. Mercier joined Gilead in 2019, following 25 years at Bristol-Myers Squibb where she held senior leadership roles with broad experience across various geographies and commercial operations. She was previously President of Bristol-Myers Squibb's large markets division, which included the U.S., Germany, Japan, and France. She is recognized for her ability to drive strong commercial execution and has overseen multiple product launches. She currently serves on the boards of Neurocrine Biosciences, Arcus Biosciences, and the University of Southern California's Leonard D. Schaeffer Center for Health Policy and Economics.
Dietmar Berger, MD, PhD, Chief Medical Officer
Dr. Berger joined Gilead Sciences as Chief Medical Officer on January 2, 2025. Before his role at Gilead, he served as Senior Vice President and Global Head of Development at Sanofi. He is a board-certified internist, hematologist, and oncologist with over 25 years of experience in developing and delivering innovative medicines. His career includes leadership positions at Atara, Genentech, Bayer, and Amgen.
Jyoti Mehra, Executive Vice President, Human Resources
Ms. Mehra is Gilead's Executive Vice President of Human Resources, a position she assumed in 2017. Prior to joining Gilead, she held senior leadership positions at Novartis Corp. across the United States, Europe, and China, bringing a broad international perspective to her work. She currently serves on the board of directors of Lam Research and California Conference for Women.
AI Analysis | Feedback
Here are the key risks to Gilead Sciences (GILD):- Patent Expirations and Generic Competition: Gilead Sciences faces significant threats from the expiration of key product patents, particularly within its highly profitable HIV franchise. These patent expirations pave the way for increased competition from generic and biosimilar drugs, which can lead to substantial erosion of market share and a reduction in revenue and profitability. For example, specific HIV treatments are facing patent expirations in 2025 and beyond.
- Clinical Trial Failures and Regulatory Setbacks: The success of Gilead's business is heavily dependent on its ability to discover, develop, and obtain regulatory approval for new pharmaceutical products. The company faces inherent risks associated with clinical trials, including the potential for unfavorable results, delays in timelines, or even outright discontinuation of programs, such as the magrolimab program. Additionally, regulatory hurdles, market access issues, and pricing pressures can delay or prevent the approval and successful launch of new products.
- Intense Market Competition: Gilead operates within a highly competitive biopharmaceutical landscape, contending with numerous large-cap pharmaceutical companies possessing extensive research and development capabilities and global marketing networks. This intense competition spans across its key therapeutic areas, including HIV and oncology, which can exert pressure on market share, pricing strategies, and overall profitability.
AI Analysis | Feedback
- Competition from long-acting injectable therapies in HIV treatment and prevention: ViiV Healthcare (a GSK joint venture) has launched and gained market share with long-acting injectable regimens like Cabenuva (for treatment) and Apretude (for PrEP). These less frequent injection options challenge Gilead's long-standing dominance and significant market share in oral daily HIV medication, potentially shifting patient preferences and eroding future revenue streams.
- Competitor success in the NASH market where Gilead has historically failed: Madrigal Pharmaceuticals recently received FDA approval for Rezdiffra (resmetirom), the first and only drug specifically for the treatment of non-alcoholic steatohepatitis (NASH). Given Gilead's significant past investments and repeated clinical trial failures in developing a NASH therapy, this approval establishes a strong first-mover competitor in a disease area Gilead had targeted, potentially limiting future market opportunities for Gilead should they eventually develop a successful drug.
AI Analysis | Feedback
Gilead Sciences (GILD) operates in several key therapeutic areas with significant addressable markets:
- HIV Drugs: The global HIV drugs market was valued at approximately $32.85 billion in 2024 and is projected to reach $45.07 billion by 2033, growing at a CAGR of 3.40% during 2025-2033. North America dominates this market, holding over 45.7% of the share in 2024. The U.S. HIV drugs market alone was valued at $7.8 billion in 2024 and is estimated to reach $12.3 billion by 2033, with a CAGR of 5.2% from 2025-2033. Gilead's flagship product, Biktarvy, holds a 52% share of the U.S. HIV treatment market.
- COVID-19 (Remdesivir/Veklury): The global Remdesivir (marketed as Veklury by Gilead Sciences) market size was valued at approximately $6.01 billion in 2023 and is predicted to grow to around $11.12 billion by 2032 with a CAGR of roughly 7.20% between 2024 and 2032. North America was the largest region in the Remdesivir market in 2024.
-
Liver Diseases (Hepatitis B and C):
- Overall Liver Disease Therapeutics: The global liver disease therapeutics market size was estimated at $20.31 billion in 2024 and is projected to reach $40.29 billion by 2033, growing at a CAGR of 7.9% from 2025 to 2033. North America held the largest share of this market in 2024, accounting for 39.87% of global revenue. Another source indicates the market size is estimated at $23.42 billion in 2025 and is expected to reach $33.84 billion by 2030, at a CAGR of 7.63% during the forecast period (2025-2030).
- Hepatitis B (HBV) Treatments: The global hepatitis B therapeutics market size was valued at $2.33 billion in 2024 and is projected to grow from $2.48 billion in 2025 to $6.25 billion in 2032. Another report indicates the global hepatitis B market size was valued at $4.78 billion in 2024 and is expected to hit around $6.65 billion by 2034, growing at a CAGR of 3.36%.
- Hepatitis C (HCV) Drugs: The global hepatitis C market size was valued at $7.95 billion in 2024 and is projected to reach approximately $10.62 billion by 2034 with a CAGR of 3% from 2025 to 2034. Another estimate places the global Hepatitis C drugs market size at $12.5 billion in 2023, poised to grow from $13.02 billion in 2024 to $18.05 billion by 2032, at a CAGR of 4.2% in the forecast period (2025-2032). Gilead Sciences holds a significant share in the United States and European Union HCV market with its Harvoni and Epclusa franchises.
- Oncology (CAR T-Cell Therapies - Yescarta, Tecartus): Yescarta (axicabtagene ciloleucel), a CAR T-cell therapy from Kite Pharma (a Gilead subsidiary), posted global sales of $1.6 billion in 2024. Yescarta accounted for the largest share of the CAR T-cell therapy market in 2023. Tecartus (brexucabtagene autoleucel), another CAR T-cell therapy from Kite, posted global sales of $403 million in 2024.
- Oncology (Trodelvy): Global sales for Trodelvy (sacituzumab govitecan) are expected to reach nearly $3 billion by 2029, driven by expansion into new indications such as NSCLC, as well as bladder, breast, and ovarian cancers globally. The global Trodelvy market is expected to surpass $3 billion by 2028.
- Inflammation (Filgotinib/Jyseleca): The global filgotinib market size was valued at approximately $1.5 billion in 2023 and is projected to reach around $4.2 billion by 2032, growing at a compound annual growth rate (CAGR) of 12.1% during the forecast period. Gilead Sciences, in collaboration with Galapagos NV, has been involved in developing and commercializing filgotinib. However, Gilead has largely scaled back its plans for U.S. approval of filgotinib in rheumatoid arthritis.
AI Analysis | Feedback
Gilead Sciences (GILD) is anticipated to drive future revenue growth over the next 2-3 years through several key factors:
- Continued Strength of the HIV Franchise: Gilead's leading HIV treatments, Biktarvy and Descovy, are expected to continue their strong performance and market share gains. Biktarvy notably holds approximately 52% of the U.S. HIV treatment market share, while Descovy accounts for over 45% of the U.S. pre-exposure prophylaxis (PrEP) market. Gilead raised its full-year HIV revenue growth expectations to approximately 5% for 2025, despite Medicare Part D redesign impacts.
- Successful Uptake of Yeztugo: The recently launched HIV prevention injectable, Yeztugo (lenacapavir), is a significant growth driver. It generated $39 million in sales in Q3 2025 and achieved 75% U.S. payer coverage ahead of schedule, with expectations for further uptake and an estimated $150 million in first-year sales.
- Growth in the Liver Disease Portfolio with Livdelzi: Livdelzi (seladelpar) for primary biliary cholangitis (PBC) has shown strong growth, with sales topping $100 million in Q3 2025 for the first time, reflecting a 35% sequential increase. This product is becoming a top therapy for second-line PBC treatment.
- Advancements and New Launches in the Oncology Pipeline: Gilead is focused on expanding its oncology footprint. Trodelvy continues to gain market share, and the company anticipates multiple potential product launches in oncology for 2026, including Trodelvy in breast cancer and anito-cel in multiple myeloma. Gilead has a long-term goal of deriving a significant portion of its revenue from oncology by 2030.
- Development of Next-Generation HIV Therapies: Gilead is advancing its pipeline with next-generation HIV treatments. Updates on studies evaluating a single-tablet regimen of bictegravir and lenacapavir are expected, with a target product launch in early 2027, further solidifying its HIV franchise.
AI Analysis | Feedback
Share Repurchases
- Gilead Sciences announced a new $6 billion share repurchase program, which will commence upon the completion of the previously approved program.
- The company's share buybacks totaled $1.15 billion in 2024, $1 billion in 2023, and $1.396 billion in 2022.
- As of September 30, 2025, Gilead had completed the repurchase of $3,918.52 million under its share buyback program announced on February 25, 2020.
Share Issuance
- Gilead's share repurchases are intended, at a minimum, to offset equity dilution, indicating ongoing issuance related to employee stock plans or similar mechanisms.
Outbound Investments
- In February 2024, Gilead acquired CymaBay Therapeutics for $4.3 billion, focusing on liver disease therapies.
- Gilead acquired Immunomedics in September 2020, significantly expanding its oncology treatment portfolio.
- Other notable acquisitions include Forty Seven, Inc. in March 2020 for $4.9 billion to enhance its oncology pipeline, and MiroBio for $405 million in August 2022.
Capital Expenditures
- Gilead's capital expenditures averaged $613 million annually from fiscal years ending December 2020 to 2024.
- The company plans a strategic investment of $32 billion in U.S.-based manufacturing and R&D through 2030.
- This investment includes $4 billion for capital projects (labs and equipment), $5 billion for technology, operations, and R&D site activities, and $2 billion for digital and advanced engineering initiatives, aimed at expanding U.S. manufacturing and R&D capabilities.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 137.22 |
| Mkt Cap | 246.9 |
| Rev LTM | 61,215 |
| Op Inc LTM | 14,892 |
| FCF LTM | 14,176 |
| FCF 3Y Avg | 13,642 |
| CFO LTM | 16,843 |
| CFO 3Y Avg | 16,176 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.3% |
| Rev Chg 3Y Avg | 1.8% |
| Rev Chg Q | 3.3% |
| QoQ Delta Rev Chg LTM | 0.9% |
| Op Mgn LTM | 25.4% |
| Op Mgn 3Y Avg | 25.1% |
| QoQ Delta Op Mgn LTM | 1.3% |
| CFO/Rev LTM | 29.9% |
| CFO/Rev 3Y Avg | 29.9% |
| FCF/Rev LTM | 25.9% |
| FCF/Rev 3Y Avg | 25.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 246.9 |
| P/S | 5.5 |
| P/EBIT | 15.3 |
| P/E | 22.0 |
| P/CFO | 18.4 |
| Total Yield | 7.6% |
| Dividend Yield | 2.8% |
| FCF Yield 3Y Avg | 6.1% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 10.9% |
| 3M Rtn | 29.3% |
| 6M Rtn | 33.9% |
| 12M Rtn | 31.7% |
| 3Y Rtn | 43.7% |
| 1M Excs Rtn | 10.7% |
| 3M Excs Rtn | 25.5% |
| 6M Excs Rtn | 30.8% |
| 12M Excs Rtn | 16.4% |
| 3Y Excs Rtn | -26.1% |
Comparison Analyses
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA220020 | YEZTUGO | lenacapavir sodium | tablet | 6182025 | 4.7% | 13.9% | 40.2% | 40.2% | 40.2% |
| NDA220018 | YEZTUGO | lenacapavir | solution | 6182025 | 4.7% | 13.9% | 40.2% | 40.2% | 40.2% |
| NDA217899 | LIVDELZI | seladelpar lysine | capsule | 8142024 | 26.1% | 41.8% | 65.7% | 110.8% | 110.8% |
| NDA215974 | SUNLENCA | lenacapavir sodium | tablet | 12222022 | -6.8% | -6.6% | -3.0% | 17.3% | 94.6% |
| NDA215973 | SUNLENCA | lenacapavir sodium | solution | 12222022 | -6.8% | -6.6% | -3.0% | 17.3% | 94.6% |
| NDA214187 | EPCLUSA | sofosbuvir | pellets | 6102021 | 3.0% | 3.5% | -8.5% | 22.7% | 158.3% |
| NDA214787 | VEKLURY | remdesivir | solution | 10222020 | 11.7% | 10.7% | 15.7% | 22.2% | 201.7% |
| NDA212480 | SOVALDI | sofosbuvir | pellets | 8282019 | 6.5% | 19.6% | 6.9% | 21.4% | 201.5% |
| NDA212477 | HARVONI | ledipasvir | pellets | 8282019 | 6.5% | 19.6% | 6.9% | 21.4% | 201.5% |
| NDA210251 | BIKTARVY | bictegravir sodium | tablet | 2072018 | -20.1% | -5.7% | -16.1% | -10.8% | 143.8% |
| ... | |||||||||
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Discovery, development and commercialization of innovative medicines in areas of unmet medical need | 27,116 | ||||
| AmBisome | 497 | 540 | 436 | 407 | |
| Biktarvy | 10,390 | 8,624 | 7,259 | 4,738 | |
| Complera/Eviplera | 200 | 258 | 269 | 406 | |
| Descovy | 1,872 | 1,700 | 1,861 | 1,500 | |
| Genvoya | 2,404 | 2,879 | 3,338 | 3,931 | |
| Ledipasvir/Sofosbuvir | 115 | 212 | 272 | 643 | |
| Letairis | 196 | 206 | 314 | 618 | |
| Odefsey | 1,469 | 1,568 | 1,672 | 1,655 | |
| Other | 253 | 281 | 195 | 285 | |
| Other Hepatitis C virus (HCV) | 166 | 207 | 193 | ||
| Other Human immunodeficiency virus (HIV) | 57 | 195 | 58 | 47 | |
| Other hepatitis B virus (HBV) / hepatitis Delta virus (HDV) | 55 | 44 | 18 | ||
| Royalty, contract and other revenues | 299 | 297 | 334 | 330 | |
| Sofosbuvir/Velpatasvir | 1,530 | 1,462 | 1,599 | 1,965 | |
| Stribild | 127 | 189 | 196 | 369 | |
| Symtuza - Revenue share | 530 | 531 | 488 | 379 | |
| Tecartus | 299 | 176 | 44 | ||
| Trodelvy | 680 | 380 | 49 | ||
| Truvada | 147 | 371 | 1,448 | 2,813 | |
| Veklury | 3,905 | 5,565 | 2,811 | ||
| Vemlidy | 842 | 814 | 657 | 488 | |
| Viread | 91 | 111 | 185 | 243 | |
| Yescarta | 1,160 | 695 | 563 | 456 | |
| Atripla | 349 | 600 | |||
| Ranexa | 9 | 216 | |||
| Zydelig | 72 | 103 | |||
| Vosevi | 257 | ||||
| Total | 27,116 | 27,284 | 27,305 | 24,689 | 22,449 |
Price Behavior
Price Behavior
| Market Price | $152.50 | |
| Market Cap ($ Bil) | 189.6 | |
| First Trading Date | 01/22/1992 | |
| Distance from 52W High | 0.0% | |
| 50 Days | 200 Days | |
| DMA Price | $127.39 | $115.67 |
| DMA Trend | up | up |
| Distance from DMA | 19.7% | 31.8% |
| 3M | 1YR | |
| Volatility | 26.5% | 29.0% |
| Downside Capture | -17.05 | 31.68 |
| Upside Capture | 121.50 | 74.61 |
| Correlation (SPY) | 8.7% | 24.3% |
GILD Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.55 | 0.65 | 0.28 | 0.30 | 0.37 | 0.35 |
| Up Beta | 1.36 | 2.04 | 0.26 | 0.43 | 0.27 | 0.33 |
| Down Beta | 0.16 | -0.15 | -0.19 | -0.13 | 0.31 | 0.35 |
| Up Capture | 218% | 161% | 105% | 70% | 62% | 17% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 12 | 22 | 33 | 64 | 132 | 395 |
| Down Capture | -103% | 14% | 2% | 17% | 46% | 52% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 8 | 19 | 28 | 60 | 117 | 352 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GILD | |
|---|---|---|---|---|
| GILD | 57.6% | 29.0% | 1.56 | - |
| Sector ETF (XLV) | 7.7% | 17.3% | 0.27 | 53.1% |
| Equity (SPY) | 15.4% | 19.4% | 0.61 | 24.7% |
| Gold (GLD) | 73.9% | 24.8% | 2.19 | -5.7% |
| Commodities (DBC) | 8.9% | 16.6% | 0.34 | -2.3% |
| Real Estate (VNQ) | 4.6% | 16.5% | 0.10 | 28.5% |
| Bitcoin (BTCUSD) | -33.5% | 42.9% | -0.83 | 0.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GILD | |
|---|---|---|---|---|
| GILD | 23.2% | 23.7% | 0.85 | - |
| Sector ETF (XLV) | 8.1% | 14.5% | 0.37 | 49.9% |
| Equity (SPY) | 14.4% | 17.0% | 0.68 | 29.8% |
| Gold (GLD) | 21.4% | 16.9% | 1.03 | 2.7% |
| Commodities (DBC) | 11.5% | 18.9% | 0.49 | 1.3% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 30.5% |
| Bitcoin (BTCUSD) | 13.9% | 57.8% | 0.46 | 5.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GILD | |
|---|---|---|---|---|
| GILD | 10.1% | 25.6% | 0.40 | - |
| Sector ETF (XLV) | 10.9% | 16.5% | 0.54 | 53.7% |
| Equity (SPY) | 15.4% | 17.9% | 0.74 | 38.1% |
| Gold (GLD) | 15.7% | 15.5% | 0.84 | 1.3% |
| Commodities (DBC) | 8.0% | 17.6% | 0.37 | 8.5% |
| Real Estate (VNQ) | 6.0% | 20.7% | 0.25 | 27.8% |
| Bitcoin (BTCUSD) | 67.1% | 66.6% | 1.07 | 4.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/30/2025 | 1.1% | 4.2% | 4.6% |
| 8/7/2025 | 8.3% | 7.9% | 5.1% |
| 4/24/2025 | -2.8% | -2.7% | 1.1% |
| 2/11/2025 | 7.5% | 12.0% | 17.9% |
| 11/6/2024 | 6.8% | 1.0% | 0.5% |
| 8/8/2024 | -2.6% | -1.7% | 4.7% |
| 4/25/2024 | 0.2% | 0.1% | 0.6% |
| 2/6/2024 | -4.2% | -5.4% | -5.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 13 | 17 |
| # Negative | 15 | 11 | 7 |
| Median Positive | 4.6% | 4.2% | 4.7% |
| Median Negative | -2.8% | -4.9% | -7.7% |
| Max Positive | 12.9% | 13.2% | 21.4% |
| Max Negative | -4.8% | -7.6% | -10.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/23/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/22/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
| 12/31/2021 | 02/23/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | O'Day, Daniel Patrick | Chairman & CEO | Direct | Sell | 12302025 | 124.83 | 10,000 | 1,248,272 | 70,739,325 | Form |
| 2 | Dickinson, Andrew D | Chief Financial Officer | Direct | Sell | 12162025 | 122.00 | 3,000 | 366,000 | 18,727,366 | Form |
| 3 | Mercier, Johanna | Chief Commercial Officer | Direct | Sell | 12162025 | 122.00 | 3,000 | 366,000 | 12,958,962 | Form |
| 4 | Bluestone, Jeffrey | Direct | Sell | 12012025 | 125.08 | 5,000 | 625,400 | 1,115,714 | Form | |
| 5 | Kramer, Kelly A | Direct | Sell | 12012025 | 127.11 | 2,806 | 356,671 | 170,200 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.